Tyck till om SwePub Sök här!
onr:"swepub:oai:lup.lub.lu.se:695f4695-1d31-42f2-8122-90df2d2620a0"
Sökning: onr:"swepub:oai:lup.lub.lu.se:695f4695-1d31-42f2-8122-90df2d2620a0" > Second primary canc...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Second primary cancers in melanoma patients critically shorten survival
-
- Zheng, Guoqiao (författare)
- Heidelberg University,German Cancer Research Centre
-
- Chattopadhyay, Subhayan (författare)
- German Cancer Research Centre,Heidelberg University
-
- Sundquist, Kristina (författare)
- Lund University,Lunds universitet,Allmänmedicin och klinisk epidemiologi,Forskargrupper vid Lunds universitet,Family Medicine and Clinical Epidemiology,Lund University Research Groups,Shimane University,Icahn School of Medicine at Mount Sinai
- visa fler...
- visa färre...
- (creator_code:org_t)
- 2020
- 2020
- Engelska 8 s.
- Ingår i: Clinical Epidemiology. - 1179-1349. ; 12, s. 105-112
- Tidskriftsartikel (refereegranskat)
Abstract
Ämnesord
Stäng
- Background: Survival in malignant cutaneous melanoma has improved but increasing survival will result in an increased likelihood of the occurrence of second primary cancers (SPCs). SPCs may adversely interfere with survival. We quantified survival in patients with different types of SPCs, in comparison to known poor prognostic indicators of metastatic disease. Methods: Data for melanoma and any SPCs were obtained from the Swedish Cancer Registry for years 2003 through 2015, including clinical TNM classification. SPCs were grouped into three ‘prognostic groups’ based on 5-year relative survival of these cancers as first primary cancer. Kaplan-Meier survival curves were generated and hazard ratios were estimated using Cox regression, adjusted for a number of variables and treating diagnosis of SPC as a time-dependent variable. Results: The total number of first melanoma patients was 28,716 followed by 3,202 (11.1%) SPCs, 1/3 of which had a second melanoma while 2/3 had other SPCs. Among men diagnosed at age over 70 years, who survived at least 10 years, 31.4% had SPC. HRs (95% CI) for survival increased systematically from the reference rate of 1.00 (no SPC) to 1.59 (1.35–1.87) with SPC of good prognosis (78.6% of SPCs) to 3.49 (2.58–4.72) of moderate prognosis (12.0%) and to 7.93 (5.50–11.44) of poor prognosis (9.4%). In patients without SPC, the HRs increased to 2.62 (2.02–3.39) with any nodal metastases and to 5.88 (4.57–7.57) with any distant metastases compared to patients without local or distant metastases. Conclusion: The data showed that SPCs are an increasingly common negative prognostic factor for melanoma. Future attempts to improve melanoma survival need to target SPCs.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Melanoma
- Metastasis
- Prognosis
- Second cancer
- Survival
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Zheng, Guoqiao
- Chattopadhyay, S ...
- Sundquist, Krist ...
- Sundquist, Jan
- Försti, Asta
- Hemminki, Akseli
- visa fler...
- Hemminki, Kari
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
- Artiklar i publikationen
- Clinical Epidemi ...
- Av lärosätet
- Lunds universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
